Prevalence of SARS-CoV-2 Genome in Tears of Asymptomatic and Moderately Symptomatic COVID-19 Patients

Study Overview
=================
Brief Summary
-----------------
To evaluate the prevalence of SARS-CoV-2 genome in patients with asymptomatic and moderately symptomatic COVID19.

Detailed Description
-----------------
Patients attending to the COVID19 screening facility of Paris South University hospital and willing to participate to the study will have both nasopharyngeal and conjunctival swab for SARS-CV-2 genome detection using PCR. The project will evaluate the prevalence of positive conjunctival swabs in patients with positive nasopharyngeal swab. These results will be corelated to symptoms of disease assessed with a standardized questionnaire.

Official Title
-----------------
Prevalence of SARS-CoV-2 Genome in Tears of Asymptomatic and Moderately Symptomatic COVID-19 Patients

Conditions
-----------------
SARS-CoV-2

Intervention / Treatment
-----------------
* Diagnostic Test: conjunctival swab


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients receiving diagnostic nasopharyngeal PCR for COVID-19 as part of the usual care Age ≥ 18. Information and signature of consent Affiliated with a social security scheme or entitled Exclusion Criteria: Refusal to participate in the study Eye surgery less than 3 months old Unable to give informed consent No coverage through the health insurance system Patient under judicial protection Patient on AME

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Patients attending to the COVID19 screening facility<br>Patients will have both nasopharyngeal and conjunctival swab for SARS-CV-2 genome detection using PCR. Study will evaluate the prevalence of positive conjunctival swabs in patients with positive nasopharyngeal swab. These results will be corelated to symptoms of disease assessed with a stan | Diagnostic Test: conjunctival swab<br>* Patients will have conjunctival swab for SARS-CV-2 genome detection<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| presence of SARS-CoV-2 genome in tears | Prevalence of SARS-CoV-2 genome in tears | at the end of the study, an average of 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| presence of systemic symptoms evaluated at the time of making an appointment by a systematic standardized interrogation | correlation between systemic symptoms (fever, chills, sweating, muscle aches, headache, runny or stuffy nose, cough, sore throat, asthenia, anosmia, agueusia, unusual shortness of breath, skin rash diarrhea, nausea vomiting) and positive conjunctival swab | at the end of the study, an average of 1 year | 
| assessement of viral load levels | correlation between nasopharyngeal viral load and conjunctival load (indirectly assessed with cycle thresholds quantification method) | at the end of the study, an average of 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
SARS-CoV-2, COVID19, conjunctiva, tears